Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease.
MannKind (MNKD) Jumps On FDA Approval Of Furoscix ReadyFlow
The FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling caused by excess fluid trapped in the body’s tissue) in adults with heart failure or chronic kidney disease.
The product is notable for being the first autoinjector delivering IV-equivalent exposure, potentially allowing for quicker symptom relief and reducing the need for emergency interventions.
Furoscix ReadyFlow provides a full 80 mg/mL dose in a simple, patient-friendly format administered in under 10 seconds.
Heart failure affects approximately 6.7 million adults in the United States and is projected to increase to more than 8 million by 2030.
Concurrently, the biopharmaceutical company announced a private placement financing of approximately $50 million.
MannKind will use the proceeds for general corporate purposes, including funding the $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow.
MNKD Technical Analysis: Key Levels And Momentum
Mannkind’s stock is currently trading at $4.20, which is 2.5% above its 20-day simple moving average (SMA) of $4.11 and 11.7% above its 50-day SMA of $3.77.
The moving average convergence divergence (MACD) is below its signal line, indicating that momentum is fading, suggesting that the recent price increase may not be sustainable unless the stock can regain upward momentum.
- Key Resistance: $4.50 — a nearby level where rebounds can stall.
- Key Support: $4.00 — a psychological level that could provide a buffer against downward pressure.
MNKD Earnings Preview And Analyst Price Targets
The countdown is on: Mannkind Corporation is set to report earnings on August 5, 2026 (estimated).
- EPS Estimate: 1 cent (Down from 5 cents YoY)
- Revenue Estimate: $108.58 million (Up from $76.53 million YoY)
How MannKind (MNKD) Ranks On Momentum And Value
Below is the Benzinga Edge scorecard for Mannkind, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 41.94) — Stock is showing weak performance indicators.
- Value: Weak (Score: 12.44) — Trading at a steep premium relative to peers.
MNKD Stock Price Activity: MannKind shares were up 6.93% at $4.16 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock